Aptamer BT200 is protective against myocardial ischemia-reperfusion injury in mice.

Myocardial ischemia-reperfusion (MI/R) injury tends to affect cardiac function and leads to poor patient prognosis, and there is still not effectively targeted drug to develop anti-Von Willebrand Factor (VWF) aptamer in acute coronary heart disease. However, the newly anti-VWF aptamer BT200 is not only applied for stroke and hemophilia, but also for anti-thrombolism function in clinical development. The role of BT200 in acute myocardial injury during MI/R is still unknown.